CSL
vs
S
S&P/ASX 300
CSL
Over the past 12 months, CSL has underperformed S&P/ASX 300, delivering a return of -23% compared to S&P/ASX 300's +1% growth.
Stocks Performance
CSL vs S&P/ASX 300
Performance Gap
CSL vs S&P/ASX 300
Performance By Year
CSL vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
CSL Ltd
Glance View
CSL Ltd is a global biopharmaceutical company that makes medicines from human plasma and other biological materials. Its main products are treatments for immune disorders, bleeding disorders, and other serious conditions, plus vaccines for influenza and related infectious diseases. The company also sells iron and kidney-care therapies through its specialty medicines business. Its customers are hospitals, clinics, blood plasma centers, doctors, public health agencies, and patients who need long-term treatment. CSL makes money by selling prescription medicines and vaccines through healthcare systems and distributors, with sales supported by contracts, tenders, and recurring demand for chronic therapies. A key part of its business is collecting plasma, turning it into purified therapies, and supplying those products to markets where there are few direct substitutes. What makes CSL different is that it sits in a highly specialized part of healthcare where safety, manufacturing skill, and access to plasma matter as much as research. It does not sell ordinary consumer products; it turns complex biological inputs into medicines that are hard to make and are often used for serious, ongoing medical needs. That gives CSL a role as a critical supplier to the healthcare system rather than a broad drugmaker focused on many small molecules.
